iBio Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation (Details)

Basis of Presentation (Details) - USD ($)							1 Months Ended			3 Months Ended				6 Months Ended		12 Months Ended
Basis of Presentation (Details) - USD ($)	Feb. 07, 2020	Jan. 01, 2020	Oct. 29, 2019	Jul. 12, 2018	Jun. 26, 2018	Nov. 30, 2017	Feb. 08, 2020	Oct. 29, 2019	Nov. 30, 2018	Dec. 31, 2019	Sep. 30, 2019	Dec. 31, 2018	Sep. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2019	Oct. 28, 2019	Jun. 30, 2018	Jun. 20, 2018
Basis of Presentation [Line Items]
Accumulated deficit										$ (135,606,000)				$ (135,606,000)		$ (105,821,000)
Net Cash Used in Operating Activities														(5,692,000)	$ (5,448,000)
Cash										$ 3,637,000		$ 13,361,000		$ 3,637,000	13,361,000	$ 4,421,000		$ 15,934,000
Net proceeds from underwritten public offering			$ 4,500,000
Proceeds from Issuance of Common Stock			4,520,000
Stock Issued During Period, Shares, New Issues					4,350,000	2,250,000
Stock Issued During Period, Value, New Issues					$ 16,000,000	$ 4,500,000
Common stock, par value (in dollars per share)										$ 0.001				$ 0.001		$ 0.001	$ 1,000		$ 1,000
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest										$ (3,764,000)	$ (4,464,000)	(4,470,000)	$ (4,399,000)	$ (8,228,000)	(8,869,000)
Shares Issued, Price Per Share						$ 2.00
Proceeds from Warrant Exercises	$ 5,400,000	$ 4,760,000												691,000	0
Contract liabilities										3,033,000				3,033,000		$ 1,279,000
Contract with Customer, Liability, Revenue Recognized										25,000				118,000
Proceeds from Contributed Capital									$ 2,500,000					0	$ 2,459,000
CC-Pharming Ltd
Basis of Presentation [Line Items]
Contract with Customer, Liability													2,900,000
Contract with Customer, Liability, Revenue Recognized														73,000		$ 1,800,000
Master Manufacturing Services and Supply Agreement ("MSA") \| Lung Bio
Basis of Presentation [Line Items]
Advance received											1,600,000
Purchase of capital expenditure														1,000,000
Related contracted services														620,000
Contract liabilities										1,600,000				1,600,000
Contract with Customer, Liability, Revenue Recognized														$ 46,000
Over-Allotment Option [Member]
Basis of Presentation [Line Items]
Proceeds from Issuance of Common Stock				$ 1,350,000
Stock Issued During Period, Shares, New Issues				1,500,000
Stock Issued During Period, Value, New Issues				$ 1,350,000
Shares Issued, Price Per Share				$ 0.90
Underwritten Public Offering [Member]
Basis of Presentation [Line Items]
Proceeds from Issuance of Common Stock			$ 5,000,000
Common Stock [Member]
Basis of Presentation [Line Items]
Stock Issued During Period, Shares, New Issues			2,450,000		4,350,000			2,450,000
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest										$ 0	$ 0	$ 0	$ 0
Shares Issued, Price Per Share					$ 0.90														0.90
Series A Warrants [Member]
Basis of Presentation [Line Items]
Stock Issued During Period, Shares, New Issues			25,000,000
Class of Warrant or Right, Issued			25,000,000											25,000,000
Class Of Warrants Or Rights Exercised	19,400,000
Series B Warrants [Member]
Basis of Presentation [Line Items]
Stock Issued During Period, Shares, New Issues			25,000,000
Class of Warrant or Right, Issued			25,000,000											25,000,000
Class Of Warrants Or Rights Exercised	5,300,000
Series A Preferred Stock [Member]
Basis of Presentation [Line Items]
Stock Issued During Period, Shares, New Issues					6,300
Preferred Stock, Par or Stated Value Per Share																			0.001
Conversion of Series C Preferred Stock into common stock, conversion price per share														$ 0.20
Preferred stock, par value (in dollars per share)																			0.001
Series B Preferred Stock [Member]
Basis of Presentation [Line Items]
Stock Issued During Period, Shares, New Issues					5,785
Shares Issued, Price Per Share			$ 0.20					$ 0.20											0.90
Preferred Stock, Par or Stated Value Per Share																			0.001
Conversion of Series C Preferred Stock into common stock, conversion price per share														$ 0.20
Preferred stock, par value (in dollars per share)																			$ 0.001
Series C Preferred Stock [Member]
Basis of Presentation [Line Items]
Stock Issued During Period, Shares, New Issues			4,510							4,490
Shares Issued, Price Per Share																	0.20
Preferred Stock, Par or Stated Value Per Share																	0.001
Preferred stock, par value (in dollars per share)																	$ 0.001
Subsequent Event [Member] \| Underwritten Public Offering [Member]
Basis of Presentation [Line Items]
Proceeds from Warrant Exercises							$ 4,700,000